0001209191-23-021649.txt : 20230330 0001209191-23-021649.hdr.sgml : 20230330 20230330175352 ACCESSION NUMBER: 0001209191-23-021649 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230329 FILED AS OF DATE: 20230330 DATE AS OF CHANGE: 20230330 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RIGGS RORY B CENTRAL INDEX KEY: 0001016835 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39329 FILM NUMBER: 23782065 MAIL ADDRESS: STREET 1: 65 RAILROAD AVE CITY: RIDGEFIELD STATE: NJ ZIP: 07657 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Royalty Pharma plc CENTRAL INDEX KEY: 0001802768 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 883-0200 MAIL ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-03-29 0 0001802768 Royalty Pharma plc RPRX 0001016835 RIGGS RORY B C/O ROYALTY PHARMA PLC 110 E. 59TH STREET NEW YORK NY 10022 1 0 0 0 0 Class A Ordinary Shares 2023-03-29 4 S 0 9926 36.95 D 1586786 D Class A Ordinary Shares 2023-03-30 4 S 0 130024 36.2575 D 1456762 D Class A Ordinary Shares 85187 I By New Ventures III LLC Class A Ordinary Shares 15000 I By Spouse The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.75 to $37.18 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.22 to $36.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Sean Weisberg, as Attorney-in-Fact for Rory B. Riggs 2023-03-30